Akebia Therapeutics (AKBA) in Focus: Stock Slumps 14.4% – Tale of the Tape

April 2, 2015 Technicals 0

Zacks

Akebia Therapeutics, Inc. (AKBA) saw a big move last session, as the company’s shares fell by over 14% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the most recent uptrend for AKBA as the stock had gained around 9% from Mar 25 to Mar 31, but slumped yesterday.

The drug company has seen a flat track record when it comes to current year estimate revisions over the past few weeks and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

AKBA currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Another better-ranked stock in the same sector is ArQule Inc. (ARQL) with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

Be the first to comment

Leave a Reply